Topic Review
Patient Blood Management in Liver Transplant
Transfusion of blood products in orthotopic liver transplantation (OLT) significantly increases post-transplant morbidity and mortality and is associated with reduced graft survival. Based on these results, an active effort to prevent and minimize blood transfusion is required. Patient blood management is a revolutionary approach defined as a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient’s own blood while promoting patient safety and empowerment. This approach is based on three pillars of treatment: (1) detecting and correcting anemia and thrombocytopenia, (2) minimizing iatrogenic blood loss, detecting, and correcting coagulopathy, and (3) harnessing and increasing anemia tolerance.
  • 1.7K
  • 13 Apr 2023
Topic Review
Persufflation (PSF)
Persufflation (PSF) utilises the organ's own vascular network to provide oxygen to the organ tissue and maintain metabolism during preservation to avoid hypoxic damage. This method discovered in the early 20th century has shown promise in providing both longer-term preservation and organ reconditioning capabilities for multiple organs including the liver, kidneys, and pancreas.
  • 917
  • 11 Nov 2021
Topic Review
Risk Factors of Rejection in Renal Transplant Recipients
Kidney transplantation (KTx) is the treatment of choice for end-stage renal diseases (ESRD). Multiple factors influence graft rejection after KTx. Pre-operative factors affecting graft function and survival include donor and recipient characteristics such as age, gender, race, and immunologic compatibility. In addition, several peri- and post-operative parameters affect graft function and rejection, such as cold and warm ischemia times, and post-operative immunosuppressive treatment. Exposure to non-self-human leucocyte antigens (HLAs) prior to transplantation up-regulates the recipient’s immune system. A higher rate of acute rejection is observed in transplant recipients with a history of pregnancies or significant exposure to blood products because these patients have higher panel reactive antibody (PRA) levels. Identifying these risk factors will help physicians to reduce the risk of allograft rejection, thereby promoting graft survival. 
  • 803
  • 18 Mar 2022
Topic Review
Spinal Cord Injury Repair
Mesenchymal stem/stromal cells (MSCs) for transplant-mediated repair represents an important and promising therapeutic strategy after spinal cord injury (SCI). MSCs can be harvested from a wide range of human tissues, however it is likely certain niches are more suited for SCI repair due to their intrinsic capabilities. 
  • 726
  • 05 May 2021
Topic Review
Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplant (HSCT) is a multi-step process with a high risk for complications during marrow ablation, during engraftment, or afterwards. Successful transplantation depends on the selection of the hematopoietic stem cell source, host preparation (conditioning regimen), and modulation of immune cell engraftment to minimize graft-versus-host disease (GVHD).
  • 699
  • 07 Aug 2021
Topic Review
Donor-Derived Cell-Free DNA in Kidney Transplantation
Donor derived cell-free DNA has been identified as a measurable lab test that may be able to adequately diagnose rejection at early stages, precluding the need for invasive procedures like biopsy.
  • 674
  • 27 Oct 2022
Topic Review
Treatment Approach for CA T-Cell Mediated Kidney Rejection
Chronic active T-cell mediated kidney rejection (CA TCMR) refers to the term that was described for the very first time during the XIII Banff Conference on Allograft Pathology in 2015 as a variant of kidney allogenic graft rejection associated with long-term graft loss. Since then, the scientific community tries to establish optimal scheme of diagnostic methods and therapeutic approach. 
  • 661
  • 27 Dec 2022
Topic Review
Muse Cells
Muse cells, identified as pluripotent surface marker, stage-specific embryonic antigen (SSEA)-3(+), are endogenous reparative pluripotent stem cells distributed in the bone marrow, peripheral blood and connective tissue of every organ. Since they are non-tumorigenic and do not require gene introduction or cytokine treatment to be rendered pluripotent and induce differentiation, they elicit few safety concerns. They can be delivered intravenously and do not require surgery for their administration since they selectively home to damaged site by sphingosine-1-phosphate (S1P)-S1PR2 axis after intravenous injection. Donor-Muse cells can be used without HLA-matching test or immunosuppressant treatment since they have a specific immunomodulatory system represented by HLA-G expression.
  • 656
  • 12 Oct 2021
Topic Review
Dyslipidemia in Renal Transplant Recipients
Dyslipidemia is a frequent complication after kidney transplantation (KT) and is an important risk factor for cardiovascular disease (CVD). Renal transplant recipients (RTRs) are considered at high, or very high, risk of CVD, which is a leading cause of death in patient group. Despite many factors of post-transplant dyslipidemia, the immunosuppressive treatment has the biggest influence on a lipid profile. There are no strict dyslipidemia treatment guidelines for RTRs, but the ones proposing an individual approach regarding CVD risk seem most suitable. Proper diet and physical activity are the main general measures to manage dyslipidemia and should be introduced initially in every patient after KT. In the case of an insufficient correction of lipemia, statins are the basis for hypolipidemic treatment. Statins should be introduced with caution to avoid serious side-effects (e.g., myopathy) or drug-drug interactions, especially with immunosuppressants. To lower the incidence of adverse effects, and improve medication adherence, ezetimibe in combination with statins is recommended. 
  • 646
  • 31 May 2022
Topic Review
Hypothermic Oxygenated Perfusion in Transplantation
Hypothermic Oxygenated Perfusion (HOPE) is a new liver preservation technique used in clinical trials. It may mitigate ischemia/reperfusion injury and improve organ function and patient outcomes.
  • 609
  • 12 Oct 2021
  • Page
  • of
  • 7